{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:39:39Z","timestamp":1790962779774,"version":"4.1.0"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK125513"],"award-info":[{"award-number":["DK125513"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Caswell Diabetes Institute of University of Michigan"},{"name":"Lipodystrophy Research Fund at University of Michigan"},{"name":"Rejuvenate Bio"},{"DOI":"10.13039\/501100007514","name":"Universit\u00e0 di Pisa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007514","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>The goal of this review is to address the challenges in diagnosing and managing lipodystrophy syndromes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Clinical and metabolic assessments, along with genetic analyses, are essential for tailoring medical care and providing appropriate genetic counseling. Efforts are underway to develop more objective diagnostic tools using imaging techniques or novel biomarkers. Leptin therapy has been a significant breakthrough for generalized lipodystrophy treatment; however, more effective treatments are still needed for partial and acquired forms. While gene editing and transcript modification strategies are being explored for specific forms of lipodystrophy, reducing the burden on adipocytes by lowering caloric intake remains a fundamental approach across all forms of the condition. As supporting data emerge, agents that reduce caloric intake may become integral to treatment algorithms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>This review offers practical guidance for clinicians managing patients with lipodystrophy, highlighting advances in diagnosis, treatment, and ongoing challenges in clinical care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11892-025-01603-4","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T05:49:29Z","timestamp":1756792169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical Guidance for Lipodystrophy Syndromes: From Diagnosis and Work-Up to Treatment"],"prefix":"10.1007","volume":"25","author":[{"given":"Donatella","family":"Gilio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Foss-Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif A.","family":"Oral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"issue":"12","key":"1603_CR1","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1210\/jc.2016-2466","volume":"101","author":"RJ Brown","year":"2016","unstructured":"Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab. 2016;101(12):4500\u201311.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1603_CR2","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1210\/jc.2011-1159","volume":"96","author":"A Garg","year":"2011","unstructured":"Garg A. Clinical review#: lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96(11):3313\u201325.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1603_CR3","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1210\/jc.2018-02730","volume":"104","author":"B Akinci","year":"2019","unstructured":"Akinci B, Oral EA, Neidert A, Rus D, Cheng WY, Thompson-Leduc P, et al. Comorbidities and survival in patients with lipodystrophy: an international chart review study. J Clin Endocrinol Metab. 2019;104(11):5120\u201335.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1603_CR4","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/cen.13311","volume":"86","author":"N Ajluni","year":"2017","unstructured":"Ajluni N, Meral R, Neidert AH, Brady GF, Buras E, McKenna B, et al. Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort. Clin Endocrinol (Oxf). 2017;86(5):698\u2013707.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1603_CR5","unstructured":"Ajluni N, Dar M, Xu J, Neidert AH, Oral EA. Efficacy and safety of metreleptin in patients with partial lipodystrophy: lessons from an expanded access program. J Diabetes Metab 2016;7(3)."},{"issue":"12","key":"1603_CR6","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1056\/NEJMra025261","volume":"350","author":"A Garg","year":"2004","unstructured":"Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350(12):1220\u201334.","journal-title":"N Engl J Med"},{"issue":"1","key":"1603_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","volume":"83","author":"A Misra","year":"2004","unstructured":"Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Med (Baltim). 2004;83(1):18\u201334.","journal-title":"Med (Baltim)"},{"issue":"3","key":"1603_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ando.2012.04.010","volume":"73","author":"MC Vantyghem","year":"2012","unstructured":"Vantyghem MC, Balavoine AS, Douillard C, Defrance F, Dieudonne L, Mouton F, et al. How to diagnose a lipodystrophy syndrome. Ann Endocrinol (Paris). 2012;73(3):170\u201389.","journal-title":"Ann Endocrinol (Paris)"},{"issue":"2","key":"1603_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/17446651.2020.1735360","volume":"15","author":"MC Foss-Freitas","year":"2020","unstructured":"Foss-Freitas MC, Akinci B, Luo Y, Stratton A, Oral EA. Diagnostic strategies and clinical management of lipodystrophy. Expert Rev Endocrinol Metab. 2020;15(2):95\u2013114.","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"2","key":"1603_CR10","first-page":"358","volume":"75","author":"A Garg","year":"1992","unstructured":"Garg A, Fleckenstein JL, Peshock RM, Grundy SM. Peculiar distribution of adipose tissue in patients with congenital generalized lipodystrophy. J Clin Endocrinol Metab. 1992;75(2):358\u201361.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1603_CR11","first-page":"381","volume":"78","author":"AJ O\u2019Sullivan","year":"1994","unstructured":"O\u2019Sullivan AJ, Kelly JJ, Hoffman DM, Freund J, Ho KK. Body composition and energy expenditure in acromegaly. J Clin Endocrinol Metab. 1994;78(2):381\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1603_CR12","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1210\/jc.2007-2780","volume":"93","author":"PU Freda","year":"2008","unstructured":"Freda PU, Shen W, Heymsfield SB, Reyes-Vidal CM, Geer EB, Bruce JN, et al. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J Clin Endocrinol Metab. 2008;93(6):2334\u201343.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1603_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1365-2265.1973.tb00411.x","volume":"2","author":"BJ Boucher","year":"1973","unstructured":"Boucher BJ, Cohen RD, Frankel RJ, Mason AS, Broadley G. Partial and total lipodystrophy: changes in Circulating sugar, free fatty acids, insulin and growth hormone following the administration of glucose and of insulin. Clin Endocrinol (Oxf). 1973;2(2):111\u201326.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1603_CR14","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1210\/clinem\/dgad491","volume":"109","author":"MC Okawa","year":"2023","unstructured":"Okawa MC, Tuska RM, Lightbourne M, Abel BS, Walter M, Dai Y, et al. Insulin signaling through the insulin receptor increases linear growth through effects on bone and the GH-IGF-1 axis. J Clin Endocrinol Metab. 2023;109(1):e96\u2013106.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1603_CR15","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.2337\/diacare.26.6.1819","volume":"26","author":"KL Herbst","year":"2003","unstructured":"Herbst KL, Tannock LR, Deeb SS, Purnell JQ, Brunzell JD, Chait A. K\u00f6bberling type of Familial partial lipodystrophy: an underrecognized syndrome. Diabetes Care. 2003;26(6):1819\u201324.","journal-title":"Diabetes Care"},{"issue":"6","key":"1603_CR16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S1262-3636(07)70227-6","volume":"31","author":"B Donadille","year":"2005","unstructured":"Donadille B, Lascols O, Capeau J, Vigouroux C. Etiological investigations in apparent type 2 diabetes: when to search for lamin A\/C mutations? Diabetes Metab. 2005;31(6):527\u201332.","journal-title":"Diabetes Metab"},{"issue":"5","key":"1603_CR17","first-page":"1776","volume":"85","author":"A Garg","year":"2000","unstructured":"Garg A. Gender differences in the prevalence of metabolic complications in Familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab. 2000;85(5):1776\u201382.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1603_CR18","doi-asserted-by":"publisher","first-page":"104028","DOI":"10.1016\/j.ejmg.2020.104028","volume":"63","author":"RCM Hennekam","year":"2020","unstructured":"Hennekam RCM. Pathophysiology of premature aging characteristics in Mendelian progeroid disorders. Eur J Med Genet. 2020;63(11):104028.","journal-title":"Eur J Med Genet"},{"issue":"2","key":"1603_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s12020-016-1002-x","volume":"54","author":"C Guill\u00edn-Amarelle","year":"2016","unstructured":"Guill\u00edn-Amarelle C, S\u00e1nchez-Iglesias S, Castro-Pais A, Rodriguez-Ca\u00f1ete L, Ord\u00f3\u00f1ez-May\u00e1n L, Pazos M, et al. Type 1 Familial partial lipodystrophy: Understanding the K\u00f6bberling syndrome. Endocrine. 2016;54(2):411\u201321.","journal-title":"Endocrine"},{"issue":"1","key":"1603_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4158\/endp.19.1.v767575m65p5mr06","volume":"19","author":"Y Handelsman","year":"2013","unstructured":"Handelsman Y, Oral EA, Bloomgarden ZT, Brown RJ, Chan JL, Einhorn D, et al. The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract. 2013;19(1):107\u201316.","journal-title":"Endocr Pract"},{"issue":"10","key":"1603_CR21","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.2337\/dc18-0978","volume":"41","author":"R Meral","year":"2018","unstructured":"Meral R, Ryan BJ, Malandrino N, Jalal A, Neidert AH, Muniyappa R, et al. Fat shadows from DXA for the qualitative assessment of lipodystrophy: when a picture is worth a thousand numbers. Diabetes Care. 2018;41(10):2255\u20138.","journal-title":"Diabetes Care"},{"issue":"8","key":"1603_CR22","doi-asserted-by":"publisher","first-page":"e512","DOI":"10.1210\/clinem\/dgad063","volume":"108","author":"SC Adiyaman","year":"2023","unstructured":"Adiyaman SC, Altay C, Kamisli BY, Avci ER, Basara I, Simsir IY, et al. Pelvis magnetic resonance imaging to diagnose Familial partial lipodystrophy. J Clin Endocrinol Metab. 2023;108(8):e512\u201320.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1603_CR23","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1210\/clinem\/dgaa137","volume":"105","author":"C Vasandani","year":"2020","unstructured":"Vasandani C, Li X, Sekizkardes H, Adams-Huet B, Brown RJ, Garg A. Diagnostic value of anthropometric measurements for Familial partial lipodystrophy, Dunnigan variety. J Clin Endocrinol Metab. 2020;105(7):2132\u201341.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1603_CR24","first-page":"161","volume":"91","author":"AS Jackson","year":"2004","unstructured":"Jackson AS, Pollock ML. Generalized equations for predicting body density of men. 1978. Br J Nutr. 2004;91(1):161\u20138.","journal-title":"Br J Nutr"},{"issue":"6","key":"1603_CR25","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1046\/j.1365-2265.1997.2081026.x","volume":"46","author":"PE Clayton","year":"1997","unstructured":"Clayton PE, Gill MS, Hall CM, Tillmann V, Whatmore AJ, Price DA. Serum leptin through childhood and adolescence. Clin Endocrinol (Oxf). 1997;46(6):727\u201333.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1603_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4274\/jcrpe.galenos.2019.2019.0124","volume":"12","author":"S \u00d6zen","year":"2020","unstructured":"\u00d6zen S, Ak\u0131nc\u0131 B, Oral EA. Current diagnosis, treatment and clinical challenges in the management of lipodystrophy syndromes in children and young people. J Clin Res Pediatr Endocrinol. 2020;12(1):17\u201328.","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"14","key":"1603_CR27","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1074\/jbc.RA118.005183","volume":"294","author":"Y Gao","year":"2019","unstructured":"Gao Y, Liu J, Bai Z, Sink S, Zhao C, Lorenzo FR, et al. Iron down-regulates leptin by suppressing protein O-GlcNAc modification in adipocytes, resulting in decreased levels of O-glycosylated CREB. J Biol Chem. 2019;294(14):5487\u201395.","journal-title":"J Biol Chem"},{"issue":"4","key":"1603_CR28","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0026-0495(97)90059-7","volume":"46","author":"P Schrauwen","year":"1997","unstructured":"Schrauwen P, van Marken Lichtenbelt WD, Westerterp KR, Saris WH. Effect of diet composition on leptin concentration in lean subjects. Metabolism. 1997;46(4):420\u20134.","journal-title":"Metabolism"},{"issue":"4","key":"1603_CR29","doi-asserted-by":"publisher","first-page":"544","DOI":"10.2337\/diabetes.47.4.544","volume":"47","author":"MF Saad","year":"1998","unstructured":"Saad MF, Khan A, Sharma A, Michael R, Riad-Gabriel MG, Boyadjian R, et al. Physiological insulinemia acutely modulates plasma leptin. Diabetes. 1998;47(4):544\u20139.","journal-title":"Diabetes"},{"issue":"5","key":"1603_CR30","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/j.1550-8528.1997.tb00668.x","volume":"5","author":"MM Hennes","year":"1997","unstructured":"Hennes MM, Dua A, Maas DL, Sonnenberg GE, Krakower GR, Kissebah AH. Relationships of plasma leptin levels to changes in plasma free fatty acids in women who are lean and women who are abdominally obese. Obes Res. 1997;5(5):442\u20136.","journal-title":"Obes Res"},{"issue":"1","key":"1603_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s001090100198","volume":"79","author":"DV Rayner","year":"2001","unstructured":"Rayner DV, Trayhurn P. Regulation of leptin production: sympathetic nervous system interactions. J Mol Med (Berl). 2001;79(1):8\u201320.","journal-title":"J Mol Med (Berl)"},{"issue":"1\u20133","key":"1603_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0167-0115(00)00154-3","volume":"92","author":"RH Unger","year":"2000","unstructured":"Unger RH. Leptin physiology: a second look. Regul Pept. 2000;92(1\u20133):87\u201395.","journal-title":"Regul Pept"},{"issue":"5","key":"1603_CR33","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1210\/jcem.87.5.8624","volume":"87","author":"WA Haque","year":"2002","unstructured":"Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab. 2002;87(5):2395.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1603_CR34","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.jacl.2018.07.009","volume":"12","author":"E Capel","year":"2018","unstructured":"Capel E, Vatier C, Cervera P, Stojkovic T, Disse E, Cottereau AS, et al. MFN2-associated lipomatosis: clinical spectrum and impact on adipose tissue. J Clin Lipidol. 2018;12(6):1420\u201335.","journal-title":"J Clin Lipidol"},{"issue":"8","key":"1603_CR35","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s40618-024-02308-3","volume":"47","author":"G Ceccarini","year":"2024","unstructured":"Ceccarini G, Pelosini C, Paoli M, Tyutyusheva N, Magno S, Gilio D, et al. Serum levels of adiponectin differentiate generalized lipodystrophies from anorexia nervosa. J Endocrinol Invest. 2024;47(8):1881\u20136.","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"1603_CR36","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1210\/jc.2009-1824","volume":"95","author":"B Antuna-Puente","year":"2010","unstructured":"Antuna-Puente B, Boutet E, Vigouroux C, Lascols O, Slama L, Caron-Debarle M, et al. Higher adiponectin levels in patients with Berardinelli-Seip congenital lipodystrophy due to Seipin as compared with 1-acylglycerol-3-phosphate-o-acyltransferase-2 deficiency. J Clin Endocrinol Metab. 2010;95(3):1463\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1603_CR37","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1056\/NEJM197602262940902","volume":"294","author":"JG Sissons","year":"1976","unstructured":"Sissons JG, West RJ, Fallows J, Williams DG, Boucher BJ, Amos N, et al. The complement abnormalities of lipodystrophy. N Engl J Med. 1976;294(9):461\u20135.","journal-title":"N Engl J Med"},{"issue":"2","key":"1603_CR38","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/00005792-200303000-00007","volume":"82","author":"A Misra","year":"2003","unstructured":"Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Med (Baltim). 2003;82(2):129\u201346.","journal-title":"Med (Baltim)"},{"issue":"1","key":"1603_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4274\/jcrpe.v2i1.39","volume":"2","author":"E Eren","year":"2010","unstructured":"Eren E, \u00d6zkan TB, \u00c7ak\u0131r ED, Sa\u011flam H, Tar\u0131m \u00d6. Acquired generalized lipodystrophy associated with autoimmune hepatitis and low serum C4 level. J Clin Res Pediatr Endocrinol. 2010;2(1):39\u201342.","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"1","key":"1603_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2337\/db21-1086","volume":"72","author":"F Corvillo","year":"2023","unstructured":"Corvillo F, Abel BS, L\u00f3pez-Lera A, Ceccarini G, Magno S, Santini F, et al. Characterization and clinical association of autoantibodies against perilipin 1 in patients with acquired generalized lipodystrophy. Diabetes. 2023;72(1):71\u201384.","journal-title":"Diabetes"},{"key":"1603_CR41","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.3389\/fimmu.2018.02142","volume":"9","author":"F Corvillo","year":"2018","unstructured":"Corvillo F, Aparicio V, L\u00f3pez-Lera A, Garrido S, Ara\u00fajo-Vilar D, de Miguel MP, et al. Autoantibodies against perilipin 1 as a cause of acquired generalized lipodystrophy. Front Immunol. 2018;9:2142.","journal-title":"Front Immunol"},{"issue":"1","key":"1603_CR42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2337\/db21-1172","volume":"72","author":"C Mandel-Brehm","year":"2023","unstructured":"Mandel-Brehm C, Vazquez SE, Liverman C, Cheng M, Quandt Z, Kung AF, et al. Autoantibodies to Perilipin-1 define a subset of acquired generalized lipodystrophy. Diabetes. 2023;72(1):59\u201370.","journal-title":"Diabetes"},{"issue":"1","key":"1603_CR43","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/ajmg.a.37880","volume":"173","author":"S Zolotov","year":"2017","unstructured":"Zolotov S, Xing C, Mahamid R, Shalata A, Sheikh-Ahmad M, Garg A. Homozygous LIPE mutation in siblings with multiple symmetric lipomatosis, partial lipodystrophy, and myopathy. Am J Med Genet A. 2017;173(1):190\u20134.","journal-title":"Am J Med Genet A"},{"issue":"12","key":"1603_CR44","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11892-018-1099-9","volume":"18","author":"B Akinci","year":"2018","unstructured":"Akinci B, Meral R, Oral EA. Phenotypic and genetic characteristics of lipodystrophy: pathophysiology, metabolic abnormalities, and comorbidities. Curr Diab Rep. 2018;18(12):143.","journal-title":"Curr Diab Rep"},{"issue":"12","key":"1603_CR45","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1046\/j.1464-5491.2002.00796.x","volume":"19","author":"WA Haque","year":"2002","unstructured":"Haque WA, Vuitch F, Garg A. Post-mortem findings in Familial partial lipodystrophy, Dunnigan variety. Diabet Med. 2002;19(12):1022\u20135.","journal-title":"Diabet Med"},{"issue":"6","key":"1603_CR46","doi-asserted-by":"publisher","first-page":"e0199052","DOI":"10.1371\/journal.pone.0199052","volume":"13","author":"JG Lima","year":"2018","unstructured":"Lima JG, Nobrega LHC, Lima NN, Dos Santos MCF, Silva PHD, Baracho MFP, et al. Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy. PLoS ONE. 2018;13(6):e0199052.","journal-title":"PLoS ONE"},{"issue":"1","key":"1603_CR47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/cen.13732","volume":"89","author":"B Akinci","year":"2018","unstructured":"Akinci B, Unlu SM, Celik A, Simsir IY, Sen S, Nur B, et al. Renal complications of lipodystrophy: a closer look at the natural history of kidney disease. Clin Endocrinol (Oxf). 2018;89(1):65\u201375.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"1603_CR48","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1210\/jc.2003-032140","volume":"89","author":"ED Javor","year":"2004","unstructured":"Javor ED, Moran SA, Young JR, Cochran EK, DePaoli AM, Oral EA, et al. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during Recombinant leptin therapy. J Clin Endocrinol Metab. 2004;89(7):3199\u2013207.","journal-title":"J Clin Endocrinol Metab"},{"key":"1603_CR49","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13098-017-0301-6","volume":"10","author":"MC Foss-Freitas","year":"2018","unstructured":"Foss-Freitas MC, Ferraz RC, Monteiro LZ, Gomes PM, Iwakura R, de Freitas LCC, et al. Endoplasmic reticulum stress activation in adipose tissue induces metabolic syndrome in individuals with Familial partial lipodystrophy of the Dunnigan type. Diabetol Metab Syndr. 2018;10:6.","journal-title":"Diabetol Metab Syndr"},{"key":"1603_CR50","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.metabol.2017.04.010","volume":"72","author":"B Akinci","year":"2017","unstructured":"Akinci B, Onay H, Demir T, Savas-Erdeve \u015e, Gen R, Simsir IY, et al. Clinical presentations, metabolic abnormalities and end-organ complications in patients with Familial partial lipodystrophy. Metabolism. 2017;72:109\u201319.","journal-title":"Metabolism"},{"issue":"2","key":"1603_CR51","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.pathol.2018.11.004","volume":"51","author":"I Hussain","year":"2019","unstructured":"Hussain I, Patni N, Garg A. Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease. Pathology. 2019;51(2):202\u201312.","journal-title":"Pathology"},{"issue":"2","key":"1603_CR52","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1172\/JCI200422382","volume":"114","author":"RA Hegele","year":"2004","unstructured":"Hegele RA, Leff T. Unbuckling lipodystrophy from insulin resistance and hypertension. J Clin Invest. 2004;114(2):163\u20135.","journal-title":"J Clin Invest"},{"issue":"4","key":"1603_CR53","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1161\/ATVBAHA.112.300962","volume":"33","author":"M Auclair","year":"2013","unstructured":"Auclair M, Vigouroux C, Boccara F, Capel E, Vigeral C, Guerci B, et al. Peroxisome proliferator-activated receptor-\u03b3 mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system. Arterioscler Thromb Vasc Biol. 2013;33(4):829\u201338.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1603_CR54","doi-asserted-by":"publisher","first-page":"684182","DOI":"10.3389\/fendo.2021.684182","volume":"12","author":"V Lambadiari","year":"2021","unstructured":"Lambadiari V, Kountouri A, Maratou E, Liatis S, Dimitriadis GD, Karpe F. Case report: metreleptin treatment in a patient with a novel mutation for Familial partial lipodystrophy type 3, presenting with uncontrolled diabetes and insulin resistance. Front Endocrinol (Lausanne). 2021;12:684182.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1603_CR55","unstructured":"Akinci B, Sahinoz M, Oral E. Lipodystrophy syndromes: presentation and treatment. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al. editors. Endotext. South Dartmouth (MA): mdtext.com, inc. Copyright \u00a9 2000\u20132024. MDText.com, Inc.; 2000."},{"issue":"9","key":"1603_CR56","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.4158\/EP.14.9.1126","volume":"14","author":"TR Joy","year":"2008","unstructured":"Joy TR, Hegele RA. Prevalence of reproductive abnormalities among women with Familial partial lipodystrophy. Endocr Pract. 2008;14(9):1126\u201332.","journal-title":"Endocr Pract"},{"issue":"1","key":"1603_CR57","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13023-020-01364-1","volume":"15","author":"D Ara\u00fajo-Vilar","year":"2020","unstructured":"Ara\u00fajo-Vilar D, Fern\u00e1ndez-Pombo A, Rodr\u00edguez-Carnero G, Mart\u00ednez-Olmos M, Cant\u00f3n A, Villar-Taibo R, et al. LipoDDx: a mobile application for identification of rare lipodystrophy syndromes. Orphanet J Rare Dis. 2020;15(1):81.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1603_CR58","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000533992","volume":"17","author":"MC Foss-Freitas","year":"2024","unstructured":"Foss-Freitas MC, Besci \u00d6, Meral R, Neidert A, Chenevert TL, Oral EA, et al. A Very-Low-Calorie diet can cause remission of diabetes mellitus and hypertriglyceridemia in Familial partial lipodystrophy. Obes Facts. 2024;17(1):103\u20138.","journal-title":"Obes Facts"},{"issue":"4","key":"1603_CR59","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ecl.2016.06.012","volume":"45","author":"I Hussain","year":"2016","unstructured":"Hussain I, Garg A. Lipodystrophy syndromes. Endocrinol Metab Clin North Am. 2016;45(4):783\u201397.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"1603_CR60","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/oby.23049","volume":"29","author":"E Koo","year":"2021","unstructured":"Koo E, Foss-Freitas MC, Meral R, Ozer M, Eldin AJ, Akinci B, et al. The metabolic equivalent BMI in patients with Familial partial lipodystrophy (FPLD) compared with those with severe obesity. Obes (Silver Spring). 2021;29(2):274\u20138.","journal-title":"Obes (Silver Spring)"},{"issue":"Suppl 1","key":"1603_CR61","first-page":"S98","volume":"43","author":"9","year":"2020","unstructured":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98\u2013110.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"1603_CR62","first-page":"S66","volume":"43","author":"6","year":"2020","unstructured":"6. Glycemic targets: standards of medical care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S66\u201376.","journal-title":"Diabetes Care"},{"issue":"4","key":"1603_CR63","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1055\/s-0031-1301284","volume":"44","author":"A Luedtke","year":"2012","unstructured":"Luedtke A, Boschmann M, Colpe C, Engeli S, Adams F, Birkenfeld AL, et al. Thiazolidinedione response in Familial lipodystrophy patients with LMNA mutations: a case series. Horm Metab Res. 2012;44(4):306\u201311.","journal-title":"Horm Metab Res"},{"issue":"4","key":"1603_CR64","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7326\/0003-4819-133-4-200008150-00009","volume":"133","author":"E Arioglu","year":"2000","unstructured":"Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med. 2000;133(4):263\u201374.","journal-title":"Ann Intern Med"},{"issue":"6","key":"1603_CR65","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.2337\/db17-1236","volume":"67","author":"M Agostini","year":"2018","unstructured":"Agostini M, Schoenmakers E, Beig J, Fairall L, Szatmari I, Rajanayagam O, et al. A Pharmacogenetic approach to the treatment of patients with PPARG mutations. Diabetes. 2018;67(6):1086\u201392.","journal-title":"Diabetes"},{"issue":"8","key":"1603_CR66","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.2337\/dc07-0141","volume":"30","author":"S Singh","year":"2007","unstructured":"Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007;30(8):2148\u201353.","journal-title":"Diabetes Care"},{"key":"1603_CR67","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.metabol.2019.05.001","volume":"96","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Perakakis N, Mantzoros CS. Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and\/or leptin replacement. Metabolism. 2019;96:66\u201382.","journal-title":"Metabolism"},{"issue":"8","key":"1603_CR68","doi-asserted-by":"publisher","first-page":"e2953","DOI":"10.1210\/clinem\/dgab216","volume":"106","author":"K Cook","year":"2021","unstructured":"Cook K, Ali O, Akinci B, Foss de Freitas MC, Montenegro RM, Fernandes VO, et al. Effect of leptin therapy on survival in generalized and partial lipodystrophy: a matched cohort analysis. J Clin Endocrinol Metab. 2021;106(8):e2953\u201367.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1603_CR69","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/dme.13527","volume":"34","author":"F Banning","year":"2017","unstructured":"Banning F, Rottenkolber M, Freibothe I, Seissler J, Lechner A. Insulin secretory defect in Familial partial lipodystrophy type 2 and successful long-term treatment with a glucagon-like peptide 1 receptor agonist. Diabet Med. 2017;34(12):1792\u20134.","journal-title":"Diabet Med"},{"issue":"4","key":"1603_CR70","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2337\/dc23-1614","volume":"47","author":"MC Foss-Freitas","year":"2024","unstructured":"Foss-Freitas MC, Imam S, Neidert A, Gomes AD, Broome DT, Oral EA. Efficacy and safety of Glucagon-Like peptide 1 agonists in a retrospective study of patients with Familial partial lipodystrophy. Diabetes Care. 2024;47(4):653\u20139.","journal-title":"Diabetes Care"},{"issue":"6","key":"1603_CR71","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.eprac.2022.03.006","volume":"28","author":"R Bansal","year":"2022","unstructured":"Bansal R, Cochran E, Startzell M, Brown RJ. Clinical effects of Sodium-Glucose transporter type 2 inhibitors in patients with partial lipodystrophy. Endocr Pract. 2022;28(6):610\u20134.","journal-title":"Endocr Pract"},{"issue":"5","key":"1603_CR72","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.2337\/diacare.28.5.1240","volume":"28","author":"E Cochran","year":"2005","unstructured":"Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care. 2005;28(5):1240\u20134.","journal-title":"Diabetes Care"},{"issue":"10","key":"1603_CR73","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1210\/jc.2017-01235","volume":"102","author":"A Melvin","year":"2017","unstructured":"Melvin A, Adams C, Flanagan C, Gaff L, Gratton B, Gribble F, et al. Roux-en-Y gastric bypass surgery in the management of Familial partial lipodystrophy type 1. J Clin Endocrinol Metab. 2017;102(10):3616\u201320.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1603_CR74","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s11605-016-3300-2","volume":"21","author":"S Grundfest-Broniatowski","year":"2017","unstructured":"Grundfest-Broniatowski S, Yan J, Kroh M, Kilim H, Stephenson A. Successful treatment of an unusual case of FPLD2: the role of Roux-en-Y gastric Bypass-Case report and literature review. J Gastrointest Surg. 2017;21(4):739\u201343.","journal-title":"J Gastrointest Surg"},{"issue":"3","key":"1603_CR75","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2265.2011.04057.x","volume":"75","author":"A Ciudin","year":"2011","unstructured":"Ciudin A, Baena-Fustegueras JA, Fort JM, Encabo G, Mesa J, Lecube A. Successful treatment for the Dunnigan-type Familial partial lipodystrophy with Roux-en-Y gastric bypass. Clin Endocrinol (Oxf). 2011;75(3):403\u20134.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"1603_CR76","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1381\/096089206778869988","volume":"16","author":"NM McGrath","year":"2006","unstructured":"McGrath NM, Krishna G. Gastric bypass for insulin resistance due to lipodystrophy. Obes Surg. 2006;16(11):1542\u20134.","journal-title":"Obes Surg"},{"issue":"6","key":"1603_CR77","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.2337\/dc06-0130","volume":"29","author":"KM Utzschneider","year":"2006","unstructured":"Utzschneider KM, Trence DL. Effectiveness of gastric bypass surgery in a patient with Familial partial lipodystrophy. Diabetes Care. 2006;29(6):1380\u20132.","journal-title":"Diabetes Care"},{"issue":"8","key":"1603_CR78","doi-asserted-by":"publisher","first-page":"e69545","DOI":"10.1371\/journal.pone.0069545","volume":"8","author":"J Settergren","year":"2013","unstructured":"Settergren J, Eiermann B, Mannheimer B. Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy\u2013a nationwide register study. PLoS ONE. 2013;8(8):e69545.","journal-title":"PLoS ONE"},{"issue":"4","key":"1603_CR79","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s40519-019-00716-6","volume":"25","author":"PF Calabr\u00f2","year":"2020","unstructured":"Calabr\u00f2 PF, Ceccarini G, Calderone A, Lippi C, Piaggi P, Ferrari F, et al. Psychopathological and psychiatric evaluation of patients affected by lipodystrophy. Eat Weight Disord. 2020;25(4):991\u20138.","journal-title":"Eat Weight Disord"},{"issue":"6 Suppl","key":"1603_CR80","doi-asserted-by":"publisher","first-page":"s55","DOI":"10.1097\/01.prs.0000285109.34527.b9","volume":"120","author":"MH Graivier","year":"2007","unstructured":"Graivier MH, Bass LS, Busso M, Jasin ME, Narins RS, Tzikas TL. Calcium hydroxylapatite (Radiesse) for correction of the mid- and lower face: consensus recommendations. Plast Reconstr Surg. 2007;120(6 Suppl):s55\u201366.","journal-title":"Plast Reconstr Surg"},{"issue":"3","key":"1603_CR81","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/00000637-198203000-00018","volume":"8","author":"PJ Hurwitz","year":"1982","unstructured":"Hurwitz PJ, Sarel R. Facial reconstruction in partial lipodystrophy. Ann Plast Surg. 1982;8(3):253\u20137.","journal-title":"Ann Plast Surg"},{"issue":"Suppl 1","key":"1603_CR82","doi-asserted-by":"publisher","first-page":"S263","DOI":"10.1097\/DSS.0000000000000870","volume":"42","author":"SH Dayan","year":"2016","unstructured":"Dayan SH, Humphrey S, Jones DH, Lizzul PF, Gross TM, Stauffer K, et al. Overview of ATX-101 (Deoxycholic acid Injection): A Nonsurgical Approach for Reduction of Submental Fat. Dermatol Surg. 2016;42(Suppl 1):S263\u201370.","journal-title":"Dermatol Surg"},{"key":"1603_CR83","unstructured":"[Available from: https:\/\/www.fda.gov\/media\/131177\/download"},{"key":"1603_CR84","unstructured":"EMA. Myalepta [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/myalepta"},{"issue":"16","key":"1603_CR85","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1001\/jama.282.16.1568","volume":"282","author":"SB Heymsfield","year":"1999","unstructured":"Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 1999;282(16):1568\u201375.","journal-title":"JAMA"},{"issue":"12","key":"1603_CR86","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1056\/NEJM199909163411204","volume":"341","author":"IS Farooqi","year":"1999","unstructured":"Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, et al. Effects of Recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341(12):879\u201384.","journal-title":"N Engl J Med"},{"issue":"6748","key":"1603_CR87","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/43448","volume":"401","author":"I Shimomura","year":"1999","unstructured":"Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 1999;401(6748):73\u20136.","journal-title":"Nature"},{"issue":"8","key":"1603_CR88","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1056\/NEJMoa012437","volume":"346","author":"EA Oral","year":"2002","unstructured":"Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346(8):570\u20138.","journal-title":"N Engl J Med"},{"issue":"1","key":"1603_CR89","doi-asserted-by":"publisher","first-page":"bvz022","DOI":"10.1210\/jendso\/bvz022","volume":"4","author":"S Grewal","year":"2020","unstructured":"Grewal S, Gubbi S, Fosam A, Sedmak C, Sikder S, Talluru H, et al. Metabolomic analysis of the effects of leptin replacement therapy in patients with lipodystrophy. J Endocr Soc. 2020;4(1):bvz022.","journal-title":"J Endocr Soc"},{"issue":"2","key":"1603_CR90","doi-asserted-by":"publisher","first-page":"324","DOI":"10.4158\/EP09155.RA","volume":"16","author":"EA Oral","year":"2010","unstructured":"Oral EA, Chan JL. Rationale for leptin-replacement therapy for severe lipodystrophy. Endocr Pract. 2010;16(2):324\u201333.","journal-title":"Endocr Pract"},{"issue":"9","key":"1603_CR91","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.1210\/jc.2003-031868","volume":"89","author":"JR McDuffie","year":"2004","unstructured":"McDuffie JR, Riggs PA, Calis KA, Freedman RJ, Oral EA, DePaoli AM, et al. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab. 2004;89(9):4258\u201363.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1603_CR92","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.metabol.2003.10.019","volume":"53","author":"SA Moran","year":"2004","unstructured":"Moran SA, Patten N, Young JR, Cochran E, Sebring N, Reynolds J, et al. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism. 2004;53(4):513\u20139.","journal-title":"Metabolism"},{"issue":"2","key":"1603_CR93","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1210\/jc.2006-1546","volume":"92","author":"K Ebihara","year":"2007","unstructured":"Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyanaga F, Kobayashi N, et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab. 2007;92(2):532\u201341.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1603_CR94","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1210\/jc.2014-4491","volume":"100","author":"T Diker-Cohen","year":"2015","unstructured":"Diker-Cohen T, Cochran E, Gorden P, Brown RJ. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. J Clin Endocrinol Metab. 2015;100(5):1802\u201310.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1603_CR95","doi-asserted-by":"publisher","first-page":"922","DOI":"10.4158\/EP11229.OR","volume":"17","author":"JL Chan","year":"2011","unstructured":"Chan JL, Lutz K, Cochran E, Huang W, Peters Y, Weyer C, et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract. 2011;17(6):922\u201332.","journal-title":"Endocr Pract"},{"issue":"1","key":"1603_CR96","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00125-009-1502-9","volume":"53","author":"AY Chong","year":"2010","unstructured":"Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia. 2010;53(1):27\u201335.","journal-title":"Diabetologia"},{"issue":"4","key":"1603_CR97","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/hep.20672","volume":"41","author":"ED Javor","year":"2005","unstructured":"Javor ED, Ghany MG, Cochran EK, Oral EA, DePaoli AM, Premkumar A, et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology. 2005;41(4):753\u201360.","journal-title":"Hepatology"},{"issue":"1","key":"1603_CR98","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2337\/diacare.26.1.30","volume":"26","author":"V Simha","year":"2003","unstructured":"Simha V, Szczepaniak LS, Wagner AJ, DePaoli AM, Garg A. Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care. 2003;26(1):30\u20135.","journal-title":"Diabetes Care"},{"issue":"10","key":"1603_CR99","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1172\/JCI0215001","volume":"109","author":"KF Petersen","year":"2002","unstructured":"Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002;109(10):1345\u201350.","journal-title":"J Clin Invest"},{"issue":"11","key":"1603_CR100","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1111\/ajt.12436","volume":"13","author":"SP Casey","year":"2013","unstructured":"Casey SP, Lokan J, Testro A, Farquharson S, Connelly A, Proietto J, et al. Post-liver transplant leptin results in resolution of severe recurrence of lipodystrophy-associated nonalcoholic steatohepatitis. Am J Transpl. 2013;13(11):3031\u20134.","journal-title":"Am J Transpl"},{"issue":"8","key":"1603_CR101","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1172\/JCI95476","volume":"128","author":"RJ Brown","year":"2018","unstructured":"Brown RJ, Valencia A, Startzell M, Cochran E, Walter PJ, Garraffo HM, et al. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy. J Clin Invest. 2018;128(8):3504\u201316.","journal-title":"J Clin Invest"},{"issue":"11","key":"1603_CR102","doi-asserted-by":"publisher","first-page":"e4327","DOI":"10.1210\/clinem\/dgab499","volume":"106","author":"ML Nguyen","year":"2021","unstructured":"Nguyen ML, Sachdev V, Burklow TR, Li W, Startzell M, Auh S, et al. Leptin attenuates cardiac hypertrophy in patients with generalized lipodystrophy. J Clin Endocrinol Metab. 2021;106(11):e4327\u201339.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1603_CR103","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1210\/jc.2005-1220","volume":"91","author":"EA Oral","year":"2006","unstructured":"Oral EA, Javor ED, Ding L, Uzel G, Cochran EK, Young JR, et al. Leptin replacement therapy modulates Circulating lymphocyte subsets and cytokine responsiveness in severe lipodystrophy. J Clin Endocrinol Metab. 2006;91(2):621\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1603_CR104","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1210\/jcem.87.7.8591","volume":"87","author":"EA Oral","year":"2002","unstructured":"Oral EA, Ruiz E, Andewelt A, Sebring N, Wagner AJ, Depaoli AM, et al. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy. J Clin Endocrinol Metab. 2002;87(7):3110\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1603_CR105","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.metabol.2004.08.021","volume":"54","author":"C Musso","year":"2005","unstructured":"Musso C, Cochran E, Javor E, Young J, Depaoli AM, Gorden P. The long-term effect of Recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. Metabolism. 2005;54(2):255\u201363.","journal-title":"Metabolism"},{"issue":"3","key":"1603_CR106","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s12020-019-01862-8","volume":"64","author":"EA Oral","year":"2019","unstructured":"Oral EA, Gorden P, Cochran E, Ara\u00fajo-Vilar D, Savage DB, Long A, et al. Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy. Endocrine. 2019;64(3):500\u201311.","journal-title":"Endocrine"},{"issue":"4","key":"1603_CR107","doi-asserted-by":"publisher","first-page":"e1739","DOI":"10.1210\/clinem\/dgab760","volume":"107","author":"R Meral","year":"2022","unstructured":"Meral R, Malandrino N, Walter M, Neidert AH, Muniyappa R, Oral EA, et al. Endogenous leptin concentrations poorly predict metreleptin response in patients with partial lipodystrophy. J Clin Endocrinol Metab. 2022;107(4):e1739\u201351.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1603_CR108","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1210\/jc.2018-02787","volume":"104","author":"H Sekizkardes","year":"2019","unstructured":"Sekizkardes H, Cochran E, Malandrino N, Garg A, Brown RJ. Efficacy of metreleptin treatment in Familial partial lipodystrophy due to PPARG vs LMNA pathogenic variants. J Clin Endocrinol Metab. 2019;104(8):3068\u201376.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2 Pt 2","key":"1603_CR109","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/AOG.0b013e31822cecf7","volume":"119","author":"M Maguire","year":"2012","unstructured":"Maguire M, Lungu A, Gorden P, Cochran E, Stratton P. Pregnancy in a woman with congenital generalized lipodystrophy: leptin\u2019s vital role in reproduction. Obstet Gynecol. 2012;119(2 Pt 2):452\u20135.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"1603_CR110","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/cen.12980","volume":"85","author":"JL Chan","year":"2016","unstructured":"Chan JL, Koda J, Heilig JS, Cochran EK, Gorden P, Oral EA, et al. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy. Clin Endocrinol (Oxf). 2016;85(1):137\u201349.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"1603_CR111","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1530\/EJE-09-1027","volume":"162","author":"J Beltrand","year":"2010","unstructured":"Beltrand J, Lahlou N, Le Charpentier T, Sebag G, Leka S, Polak M, et al. Resistance to leptin-replacement therapy in Berardinelli-Seip congenital lipodystrophy: an immunological origin. Eur J Endocrinol. 2010;162(6):1083\u201391.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1603_CR112","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1586\/17512433.2016.1096772","volume":"9","author":"CA Meehan","year":"2016","unstructured":"Meehan CA, Cochran E, Kassai A, Brown RJ, Gorden P. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Expert Rev Clin Pharmacol. 2016;9(1):59\u201368.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"1603_CR113","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/10428194.2015.1040015","volume":"57","author":"RJ Brown","year":"2016","unstructured":"Brown RJ, Chan JL, Jaffe ES, Cochran E, DePaoli AM, Gautier JF, et al. Lymphoma in acquired generalized lipodystrophy. Leuk Lymphoma. 2016;57(1):45\u201350.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"1603_CR114","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/ijd.12185","volume":"54","author":"A Aslam","year":"2015","unstructured":"Aslam A, Savage DB, Coulson IH. Acquired generalized lipodystrophy associated with peripheral T cell lymphoma with cutaneous infiltration. Int J Dermatol. 2015;54(7):827\u20139.","journal-title":"Int J Dermatol"},{"issue":"6","key":"1603_CR115","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","volume":"16","author":"EA Oral","year":"2022","unstructured":"Oral EA, Garg A, Tami J, Huang EA, O\u2019Dea LSL, Schmidt H, et al. Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with Familial partial lipodystrophy: results of the BROADEN study: volanesorsen in FPLD; the BROADEN study. J Clin Lipidol. 2022;16(6):833\u201349.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"1603_CR116","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jacl.2022.06.011","volume":"16","author":"M Lightbourne","year":"2022","unstructured":"Lightbourne M, Startzell M, Bruce KD, Brite B, Muniyappa R, Skarulis M, et al. Volanesorsen, an antisense oligonucleotide to Apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy. J Clin Lipidol. 2022;16(6):850\u201362.","journal-title":"J Clin Lipidol"},{"key":"1603_CR117","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.omtm.2022.09.014","volume":"27","author":"N Sommer","year":"2022","unstructured":"Sommer N, Roumane A, Han W, Delibegovi\u0107 M, Rochford JJ, McIlroy GD. Gene therapy restores adipose tissue and metabolic health in a pre-clinical mouse model of lipodystrophy. Mol Ther Methods Clin Dev. 2022;27:206\u201316.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"5","key":"1603_CR118","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1530\/EJE-12-0969","volume":"168","author":"Z Ahmad","year":"2013","unstructured":"Ahmad Z, Subramanyam L, Szczepaniak L, Simha V, Adams-Huet B, Garg A. Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial. Eur J Endocrinol. 2013;168(5):771\u20138.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1603_CR119","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12944-021-01589-4","volume":"20","author":"MC Foss-Freitas","year":"2021","unstructured":"Foss-Freitas MC, Akinci B, Neidert A, Bartlett VJ, Hurh E, Karwatowska-Prokopczuk E, et al. Selective targeting of angiopoietin-like 3 (ANGPTL3) with Vupanorsen for the treatment of patients with Familial partial lipodystrophy (FPLD): results of a proof-of-concept study. Lipids Health Dis. 2021;20(1):174.","journal-title":"Lipids Health Dis"},{"issue":"7","key":"1603_CR120","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","volume":"128","author":"GAM Sanchez","year":"2018","unstructured":"Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1\/2 Inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041\u201352.","journal-title":"J Clin Invest"},{"issue":"723","key":"1603_CR121","doi-asserted-by":"publisher","first-page":"eadd4897","DOI":"10.1126\/scitranslmed.add4897","volume":"15","author":"JY Altarejos","year":"2023","unstructured":"Altarejos JY, Pangilinan J, Podgrabinska S, Akinci B, Foss-Freitas M, Neidert AH, et al. Preclinical, randomized phase 1, and compassionate use evaluation of REGN4461, a leptin receptor agonist antibody for leptin deficiency. Sci Transl Med. 2023;15(723):eadd4897.","journal-title":"Sci Transl Med"},{"key":"1603_CR122","doi-asserted-by":"crossref","unstructured":"Akinci B, Meral R, Rus D, Hench R, Neidert AH, DiPaola F et al. The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide. Endocrinol Diabetes Metab Case Rep. 2020;2020.","DOI":"10.1530\/EDM-19-0139"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-025-01603-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11892-025-01603-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-025-01603-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:04:10Z","timestamp":1770296650000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11892-025-01603-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":122,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1603"],"URL":"https:\/\/doi.org\/10.1007\/s11892-025-01603-4","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"31 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Dr. Elif A. Oral In the lipodystrophy space consults with and receives clinical trial and grant support from Amryt Pharmaceuticals now part of Chiesi, Regeneron Pharmaceuticals and Ionis Pharmaceuticals. She consults with Third Rock Ventures (now formed Marea Therapeutics) and Rejuvenate Inc. Grant money from PTC Therapeutics was also received in the last 2 years. She also has IP rights to metreleptin manufactured by Amryt Pharmaceuticals, now part of Chiesi and is entitled to royalty payments. Unrelated to lipodystrophy, Dr. Oral has ongoing clinical trial support from Novo Nordisk, Rhythm Pharmaceuticals, and Morphic Medical (formerly GI Dynamics). The other authors report no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"47"}}